BMRN · NASDAQ · Biotechnology
Biotechnology company based in San Rafael, California.
In the last 90 days, no insider of BioMarin Pharmaceutical reported an open-market purchase and 1 open-market sale worth about $1.16M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$57.54
Last 12 months
Not enough history
Market value
$11.1B
Revenue
$990M
+19.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$738M
This quarter $139M, a year earlier $168M
Net debt
$3.31B
Debt $4.19B, cash $874M, at Jun 30, 2026
Net income, last 12 months
$73M
Operating profit covers interest 2x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
1 sale
$1.16M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$3.22B
+12.9% vs the year before
Net income, fiscal 2025
$349M
As reported in the annual filing
Shares outstanding
194M
As of Jul 28, 2026
Stock since the trade −14.1% · S&P 500 +1.3% · to Oct 5
BioMarin Pharmaceutical's Chief Legal Officer sold $1.16M of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade +6.3% · S&P 500 +5.9% · to Oct 5
BioMarin Pharmaceutical's Chief R&D Officer sold $177K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −4.6% · S&P 500 +14.6% · to Oct 5
BioMarin Pharmaceutical's Chief Technical Officer sold $997K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −5.8% · S&P 500 +12.4% · to Oct 5
BioMarin Pharmaceutical's Chief Legal Officer sold $1.6M of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Stock since the trade −5.8% · S&P 500 +12.4% · to Oct 5
BioMarin Pharmaceutical's Chief R&D Officer sold $382K of BioMarin Pharmaceutical shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $55.61 on Oct 6, 2025 to $57.54 on Oct 5, 2026 (+3.5%). Disclosed activity in the last 12 months: 0 insider purchases, 5 insider sales, 0 Congress purchases, 0 Congress sales.
6 active phase 3 trials and 10 active phase 2 trials led by this company, mostly in achondroplasia, hypochondroplasia, phenylketonuria (pku). The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
